Previous 10 | Next 10 |
Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present ...
2023-03-16 14:30:04 ET MediWound Ltd. (MDWD) Q4 2022 Earnings Conference Call March 16, 2023, 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call ...
2023-03-16 07:30:19 ET MediWound ( NASDAQ: MDWD ) appointed Ms. Hani Luxenburg as its new CFO, effective May 14, 2023, replacing Mr. Boaz Gur-Lavie, who served in the role for last year years. Mr. Gur-Lavie will remain with the company through...
2023-03-16 07:14:27 ET MediWound press release ( NASDAQ: MDWD ): Q4 EPS of -$1.18 may not be comparable to consensus of -$0.55. The increase in loss was due to non-cash financial expenses, primarily due to the warrant's revaluation from the September and October 2022 finan...
2022 total revenues of $26.5 million FDA approval of NexoBrid ® in December 2022 ; U.S. commercial availability expected in the second quarter of 2023 EscharEx ® Phase III protocol design is under review by the FDA; study to be initi...
2023-03-15 13:25:55 ET MediWound ( NASDAQ: MDWD ) is scheduled to announce Q4 earnings results on Thursday, March 16th, before market open. The consensus EPS Estimate is -$0.55 (-266.7% Y/Y) and the consensus Revenue Estimate is $6.6M (+20.2% Y/Y). Over the last 1 year...
Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both b ring extensive leadership experience and expertise in wound care and r egene...
YAVNE, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth ...
YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced management will present at two upcomin...
YAVNE, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct offer...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...